Rftech

알에프텍 · 061040

Information Technology Hardware & Devices · KOSDAQ

Small-cap

Market cap US$51.5M (₩71B)

Overview

Rftech makes smartphone accessories and add-on components, as well as aesthetic medical products, including hyaluronic acid dermal fillers (injectable gels that smooth wrinkles and add volume to skin) and botulinum toxin biologics (used to reduce wrinkles).

It supplies smartphone accessory products to handset-related customers under an ODM (original design manufacturer) model, meaning it designs and produces goods under the customer's own brand. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company operates across two distinct business lines: IT mobile components and bio-pharmaceutical products.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$192.8M
▼ −25.8% YoY
Operating profit · FY2025
−US$18.3M
Turned to loss
Net income · FY2025
−US$22.1M
Loss widened

Revenue

  • FY2023US$227.8M
  • FY2024US$259.7M
  • FY2025US$192.8M

Operating profit

  • FY2023US$3.7M
  • FY2024US$1.3M
  • FY2025−US$18.3M

Net income

  • FY2023US$1.1M
  • FY2024−US$14.7M
  • FY2025−US$22.1M

Key ratios (FY2025)

ROE
-16.4%
Debt/Eq
119.0%
Op. margin
-9.5%
Net margin
-11.4%
Rev. YoY
▼ −25.8%

Why it matters

Rftech has established overseas subsidiaries in China, Vietnam, the Americas, and India to support its smartphone accessories business globally.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.